Abstract
Voltage-gated sodium channels (NaV) are well validated targets for treating pain based both on human genetics and clinical experience. Consequently, there is an extensive literature on sodium channels for the treatment of pain and a number of excellent and thorough reviews have recently appeared; a selection of these is provided. This review does not attempt to evaluate all aspects of the studies in this area, but rather will focuses on several key issues that are incompletely addressed in prior reviews or that represent very recent additions to the literature. Key questions that arise are: 1) How much channel block is required to observe efficacy against neuropathic or inflammatory pain? 2) How can one improve upon the therapeutic index of previously tested NaV blockers?
Keywords: Analgesia, NaV, pain, voltage-gated sodium channel, channel block, efficacy, neuropathic or inflammatory pain, therapeutic index, ANALGESIC ACTIVITY, inflammed tissue, PET ligands
Current Pharmaceutical Biotechnology
Title: Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain
Volume: 12 Issue: 10
Author(s): Charles J. Cohen
Affiliation:
Keywords: Analgesia, NaV, pain, voltage-gated sodium channel, channel block, efficacy, neuropathic or inflammatory pain, therapeutic index, ANALGESIC ACTIVITY, inflammed tissue, PET ligands
Abstract: Voltage-gated sodium channels (NaV) are well validated targets for treating pain based both on human genetics and clinical experience. Consequently, there is an extensive literature on sodium channels for the treatment of pain and a number of excellent and thorough reviews have recently appeared; a selection of these is provided. This review does not attempt to evaluate all aspects of the studies in this area, but rather will focuses on several key issues that are incompletely addressed in prior reviews or that represent very recent additions to the literature. Key questions that arise are: 1) How much channel block is required to observe efficacy against neuropathic or inflammatory pain? 2) How can one improve upon the therapeutic index of previously tested NaV blockers?
Export Options
About this article
Cite this article as:
J. Cohen Charles, Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain, Current Pharmaceutical Biotechnology 2011; 12 (10) . https://dx.doi.org/10.2174/138920111798357249
DOI https://dx.doi.org/10.2174/138920111798357249 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Therapeutic Implications of Gene Deletion of Ligands and Receptors of Members of TNF Superfamily
Medicinal Chemistry Reviews - Online (Discontinued) The Medical Implications of Gastrointestinal Vagal Afferent Pathways in Nausea and Vomiting
Current Pharmaceutical Design The Role of SPECT and MRI for Pre and Postoperative Evaluation of Childhood Moyamoya Disease: Case Report and Review of Literature
Current Medical Imaging Alternative Gene Therapy Strategies for the Repair of Craniofacial Bone Defects
Current Gene Therapy Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
Current Drug Targets Association between the Use of Inhaled Corticosteroids and Pulmonary Nontuberculous Mycobacterial Infection: A Systematic Review
Current Respiratory Medicine Reviews Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials
Current Drug Targets ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design HIV and Respiratory Disease: A Contemporary Perspective
Current Respiratory Medicine Reviews Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Prostacyclin Receptor Regulation --- from Transcription to Trafficking
Current Molecular Medicine Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research